127 related articles for article (PubMed ID: 32862383)
1. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma.
Luo B; Yun X; Li J; Fan R; Guo WW; Liu C; Lin YD; Ge YY; Zeng X; Bi SQ; Nong WX; Zhang QM; Xie XX
Curr Med Sci; 2020 Aug; 40(4):719-728. PubMed ID: 32862383
[TBL] [Abstract][Full Text] [Related]
2. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters.
Luo B; Yun X; Fan R; Lin YD; He SJ; Zhang QM; Mo FR; Chen F; Xiao SW; Xie XX
Int J Clin Exp Pathol; 2013; 6(12):2835-45. PubMed ID: 24294369
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.
Fu J; Luo B; Guo WW; Zhang QM; Shi L; Hu QP; Chen F; Xiao SW; Xie XX
Int J Clin Exp Pathol; 2015; 8(7):7786-97. PubMed ID: 26339343
[TBL] [Abstract][Full Text] [Related]
4. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.
Tammela J; Uenaka A; Ono T; Noguchi Y; Jungbluth AA; Mhawech-Fauceglia P; Qian F; Schneider S; Sharma S; Driscoll D; Lele S; Old LJ; Nakayama E; Odunsi K
Int J Oncol; 2006 Oct; 29(4):903-10. PubMed ID: 16964386
[TBL] [Abstract][Full Text] [Related]
5. Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.
Li X; Yan J; Fan R; Luo B; Zhang Q; Lin Y; Zhou S; Luo G; Xie X; Xiao S
Oncol Lett; 2017 May; 13(5):3080-3086. PubMed ID: 28529561
[TBL] [Abstract][Full Text] [Related]
6. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells.
Okumura H; Noguchi Y; Uenaka A; Aji T; Ono T; Nakagawa K; Aoe M; Shimizu N; Nakayama E
Microbiol Immunol; 2005; 49(11):1009-16. PubMed ID: 16301813
[TBL] [Abstract][Full Text] [Related]
7. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.
Ono T; Kurashige T; Harada N; Noguchi Y; Saika T; Niikawa N; Aoe M; Nakamura S; Higashi T; Hiraki A; Wada H; Kumon H; Old LJ; Nakayama E
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3282-7. PubMed ID: 11248070
[TBL] [Abstract][Full Text] [Related]
8. Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays.
Fan R; Huang W; Luo B; Zhang QM; Xiao SW; Xie XX
Eur J Gynaecol Oncol; 2015; 36(3):298-303. PubMed ID: 26189257
[TBL] [Abstract][Full Text] [Related]
9. [Melanoma antigen-3 expression in human hepatocellular carcinoma].
Cai S; Zhao H; Leng X; Cheng J; Gong S; Peng J; Cong X; Wang Y; Rui J; Hui Y; Du R; Chen W
Zhonghua Wai Ke Za Zhi; 2000 Sep; 38(9):693-6. PubMed ID: 11832142
[TBL] [Abstract][Full Text] [Related]
10. OY-TES-1 may regulate the malignant behavior of liver cancer via NANOG, CD9, CCND2 and CDCA3: a bioinformatic analysis combine with RNAi and oligonucleotide microarray.
Hu Q; Fu J; Luo B; Huang M; Guo W; Lin Y; Xie X; Xiao S
Oncol Rep; 2015 Apr; 33(4):1965-75. PubMed ID: 25673160
[TBL] [Abstract][Full Text] [Related]
11. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
14. Expression of cancer-testis antigens in hepatocellular carcinoma.
Zhao L; Mou DC; Leng XS; Peng JR; Wang WX; Huang L; Li S; Zhu JY
World J Gastroenterol; 2004 Jul; 10(14):2034-8. PubMed ID: 15237429
[TBL] [Abstract][Full Text] [Related]
15. Expression of the nonclassical HLA class I and MICA/B molecules in human hepatocellular carcinoma.
Chen A; Shen Y; Xia M; Xu L; Pan N; Yin Y; Miao F; Shen C; Xie W; Zhang J
Neoplasma; 2011; 58(5):371-6. PubMed ID: 21744989
[TBL] [Abstract][Full Text] [Related]
16. [The expression and clinopathological significance of miR-130b in human hepatocellular carcinoma].
Xu Q; Cai W; Zhang M; Liu Q; Liu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):387-92. PubMed ID: 26927562
[TBL] [Abstract][Full Text] [Related]
17. [OCT4 expression in hepatocellular carcinoma and its clinical significance].
Huang PZ; Lu CL; Li BK; Hong J; Huang L; Wang L; Zhang Y; Yuan YF
Chin J Cancer; 2010 Jan; 29(1):111-16. PubMed ID: 20038322
[TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of hepatocellular cancer antigen genes in human hepatocellular carcinoma].
Wang WX; Leng XS; Peng JR; Mu DC; Wang Y; Zhu JY; Du RY; Chen WF
Zhonghua Wai Ke Za Zhi; 2003 Jul; 41(7):506-8. PubMed ID: 12921655
[TBL] [Abstract][Full Text] [Related]
19. Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma.
Lin A; Chen HX; Zhu CC; Zhang X; Xu HH; Zhang JG; Wang Q; Zhou WJ; Yan WH
J Cell Mol Med; 2010 Aug; 14(8):2162-71. PubMed ID: 19799650
[TBL] [Abstract][Full Text] [Related]
20. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma.
Zhang S; Li J; Wang X
Tumour Biol; 2016 Oct; 37(10):14059-14067. PubMed ID: 27507614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]